Cargando…

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours

BACKGROUND: This Phase I study evaluated continuous- and intermittent-dosing (every other week) of afatinib plus nintedanib in patients with advanced solid tumours. METHODS: In the dose-escalation phase (n=45), maximum tolerated doses (MTDs) were determined for continuous/intermittent afatinib 10, 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bahleda, Rastislav, Hollebecque, Antoine, Varga, Andrea, Gazzah, Anas, Massard, Christophe, Deutsch, Eric, Amellal, Nadia, Farace, Françoise, Ould-Kaci, Mahmoud, Roux, Flavien, Marzin, Kristell, Soria, Jean-Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815889/ https://www.ncbi.nlm.nih.gov/pubmed/26512876 http://dx.doi.org/10.1038/bjc.2015.374

Ejemplares similares

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
por: Bahleda, Rastislav, et al.
Publicado: (2018)

Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers
por: Baldini, Capucine, et al.
Publicado: (2022)

Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
por: Gazzah, Anas, et al.
Publicado: (2013)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects
por: Luedtke, Doreen, et al.
Publicado: (2018)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic
por: Bayle, Arnaud, et al.
Publicado: (2021)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
por: Négrier, Sylvie, et al.
Publicado: (2017)

1617P Sustained cancer clinical trial activity during the COVID-19 pandemic
por: Bayle, A., et al.
Publicado: (2021)

A Drug–Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
por: Vonk, Madelon C., et al.
Publicado: (2021)

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
por: Recondo, Gonzalo, et al.
Publicado: (2020)

Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?
por: Martin-Romano, Patricia, et al.
Publicado: (2021)

Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
por: Nasser, Mouhamad, et al.
Publicado: (2021)

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
por: Cabel, Luc, et al.
Publicado: (2018)

A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials
por: Kempf, Emmanuelle, et al.
Publicado: (2016)

Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF): An 8-year Observational Study at a Single Center
por: Izzedine, Hassan, et al.
Publicado: (2014)

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
por: Gordon, Michael S., et al.
Publicado: (2012)

Patient-reported tolerability of adverse events in phase 1 trials
por: Henon, Clémence, et al.
Publicado: (2017)

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020)

Bullous pemphigoid associated with nintedanib
por: Hasson, Amelia M., et al.
Publicado: (2019)

Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
por: Zhang, Li, et al.
Publicado: (2023)

Focus on Nintedanib in NSCLC and Other Tumors
por: Manzo, Anna, et al.
Publicado: (2016)

Nintedanib ameliorates animal model of dermatitis
por: Heo, Min-Jeong, et al.
Publicado: (2020)

Nintedanib-Induced Renal Thrombotic Microangiopathy
por: Fujita, Takeshi, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
por: Wind, Sven, et al.
Publicado: (2016)

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?
por: Watson, Sarah, et al.
Publicado: (2018)

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
por: Marshall, John, et al.
Publicado: (2012)

Nintedanib in advanced NSCLC: management of adverse events
por: Lemmens, Liesbeth
Publicado: (2016)

The adoption of nintedanib in systemic sclerosis: the SENSCIS study
por: Bruni, Teresa, et al.
Publicado: (2020)

Nintedanib-Induced Colitis Treated Effectively With Budesonide
por: Amini, Afshin, et al.
Publicado: (2020)

Effects of Nintedanib in an Animal Model of Liver Fibrosis
por: Wollin, Lutz, et al.
Publicado: (2020)

The Effect of Nintedanib on T-Cell Activation, Subsets and Functions
por: Ubieta, Kenia, et al.
Publicado: (2021)

Methylprednisolone/nintedanib: Lack of efficacy: case report
Publicado: (2022)

“Liquid elbows” due to afatinib administration
por: Zarogoulidis, Paul, et al.
Publicado: (2017)

Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence
por: Dercle, Laurent, et al.
Publicado: (2017)

Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
por: Antoniu, Sabina A
Publicado: (2012)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Profile of nintedanib in the treatment of solid tumors: the evidence to date
por: Awasthi, Niranjan, et al.
Publicado: (2015)

Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
por: Tomioka, Hiromi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bp4jc17fhsvdm6l4urqinlrtlt